Clinical trial
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
NCT00035334 · Bellus Health Inc. - a GSK company, Industry · Completed
Key facts
| NCT number | NCT00035334 |
|---|---|
| Title | Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis |
| Official title | A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis |
| Lead sponsor | Bellus Health Inc. - a GSK company, Industry |
| Collaborators | FDA Office of Orphan Products Development U.S. Fed |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome, Kidney Diseases, Gastrointestinal Diseases |
| Intervention type | Drug |
| Interventions | NC-503 (Anti-amyloidotic (AA) Agent) |
| Enrollment | 150 |
| Start date | Oct 1, 2001 |
| Completion | Dec 1, 2004 |
| First posted | May 3, 2002 |
| Last update posted | Feb 14, 2006 |
| Countries | Finland, France, Israel, Italy, Lithuania, Netherlands, Poland, Russia, Spain, Turkey (Türkiye), United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: